EE03741B1 - N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine - Google Patents

N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine

Info

Publication number: EE03741B1
Authority: EE; Estonia
Prior art keywords: aminoindan; propargyl; enantiomer; salts; compositions
Prior art date: 1995-05-22

Application number

EE9700310A

Other languages

English (en)

Estonian (et)

Other versions

EE9700310A (et

Inventor

B. H. Youdim Moussa

P. M. Finberg John

Levy Ruth

Sterling Jeffrey

Lerner David

Yellin Haim

Veinberg Alex

Original Assignee

Teva Pharmaceutical Industries, Ltd.

Technion Research And Development Foundation Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-22

Filing date

1996-05-22

Publication date

2002-06-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23772591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03741(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-05-22 Application filed by Teva Pharmaceutical Industries, Ltd., Technion Research And Development Foundation Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.

1998-06-15 Publication of EE9700310A publication Critical patent/EE9700310A/xx

2002-06-17 Publication of EE03741B1 publication Critical patent/EE03741B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

EE9700310A 1995-05-22 1996-05-22 N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine EE03741B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/446,439 US5744500A (en)	1990-01-03	1995-05-22	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
PCT/US1996/007465 WO1996037199A1 (en)	1995-05-22	1996-05-22	Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof

Publications (2)

Publication Number	Publication Date
EE9700310A EE9700310A (et)	1998-06-15
EE03741B1 true EE03741B1 (et)	2002-06-17

Family

ID=23772591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9700310A EE03741B1 (et)	1995-05-22	1996-05-22	N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine

Country Status (21)

Country	Link
US (6)	US5744500A (xx)
EP (1)	EP0828485A4 (xx)
JP (1)	JP3341898B2 (xx)
KR (1)	KR100412154B1 (xx)
CN (1)	CN1096853C (xx)
AU (1)	AU699090B2 (xx)
BR (1)	BR9608733A (xx)
CA (1)	CA2221458A1 (xx)
CZ (1)	CZ288724B6 (xx)
EE (1)	EE03741B1 (xx)
HU (1)	HUP9901629A3 (xx)
IL (1)	IL118247A (xx)
LT (1)	LT4455B (xx)
LV (1)	LV12083B (xx)
MX (1)	MX9708977A (xx)
NO (1)	NO975331L (xx)
NZ (1)	NZ308866A (xx)
PL (1)	PL184124B1 (xx)
RU (1)	RU2203653C2 (xx)
SK (1)	SK283675B6 (xx)
WO (1)	WO1996037199A1 (xx)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5914349A (en) *	1994-01-10	1999-06-22	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5726969A (en) *	1994-12-28	1998-03-10	Matsushita Electric Industrial Co., Ltd.	Optical recording medium having dual information surfaces
IL118836A (en) *	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
GB9715082D0 (en) *	1997-07-17	1997-09-24	Scherer Ltd R P	Treatment of attention deficit hyperactivity disorder and narcolepsy
US6232326B1 (en)	1998-07-14	2001-05-15	Jodi A. Nelson	Treatment for schizophrenia and other dopamine system dysfunctions
AU775885B2 (en)	1999-10-27	2004-08-19	Teva Pharmaceutical Industries Ltd.	Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
AU2002354017B2 (en)	2001-11-05	2007-08-16	Krele Pharmaceuticals, Inc.	Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (ja) *	2002-11-07	2011-08-24	テクニオンリサーチアンドディベラップメントファウンデイションリミテッド	神経保護鉄キレート剤及びそれを含む医薬組成物
EP2526944B1 (en)	2002-11-15	2016-06-01	Teva Pharmaceutical Industries Limited	Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040176430A1 (en) *	2002-11-21	2004-09-09	Jeffrey Sterling	Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
CN1605336A (zh) *	2003-10-10	2005-04-13	中国医学科学院药物研究所	左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
US8097608B2 (en) *	2003-11-25	2012-01-17	Technion Research And Development Foundation Ltd.	Methods for treatment of cardiovascular disorders and diseases
EP2433626B1 (en)	2003-11-25	2015-11-04	Technion Research & Development Foundation Ltd.	Compositions and methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) *	2004-02-03	2005-09-02	Technion Research & Development Foundation Ltd	神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) *	2004-02-27	2005-09-08	Jeffrey Sterling	Diamino thiazoloindan derivatives and their use
JP2008507586A (ja) *	2004-07-26	2008-03-13	テバファーマシューティカルインダストリーズリミティド	ラサグリンを含む、医薬投与剤
WO2006014968A2 (en) *	2004-07-27	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20060025446A1 (en) *	2004-07-27	2006-02-02	Jeffrey Sterling	Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
WO2006089164A1 (en) *	2005-02-17	2006-08-24	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20090124993A1 (en)	2005-02-17	2009-05-14	Burkly Linda C	Treating neurological disorders
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
KR20070111534A (ko) *	2005-02-23	2007-11-21	테바 파마슈티컬 인더스트리즈 리미티드	함량 균일성이 개선된 라사길린 제형
AU2006216509B8 (en) *	2005-02-24	2012-11-01	Technion Research And Development Foundation Ltd	Formulations of ladostigil tartrate
ES2432564T3 (es)	2005-05-10	2013-12-04	Biogen Idec Ma Inc.	Tratamiento y evaluación de trastornos inflamatorios
WO2006130726A2 (en) *	2005-06-01	2006-12-07	Teva Pharmaceutical Industries, Ltd.	Use of ladostigil for the treatment of multiple sclerosis
FR2886549B1 (fr) *	2005-06-06	2007-09-07	Biocodex	Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux
US8263655B2 (en) *	2005-10-06	2012-09-11	Technion Research And Development Foundation Ltd	Methods for treatment of renal failure
US7491847B2 (en) *	2005-11-17	2009-02-17	Teva Pharmaceutical Industries, Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
EP1956904B1 (en) *	2005-12-09	2017-04-12	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Low-dose ladostigil for the treatment of mild cognitive impairment
US20070135518A1 (en) *	2005-12-09	2007-06-14	Marta Weinstock-Rosin	Use of low-dose ladostigil for neuroprotection
US20110047685A1 (en) *	2006-02-16	2011-03-03	Ferrara Vincent R	Impact energy management method and system
US8809310B2 (en)	2006-02-21	2014-08-19	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) *	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
EP2007369A4 (en)	2006-04-03	2009-07-01	Teva Pharma	USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
CN101062897B (zh) *	2006-04-25	2011-11-23	重庆医药工业研究院有限责任公司	一种制备2，3-二氢-1h-茚-1-胺及其衍生物的改进方法
EP1892233A1 (de) *	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) *	2006-12-14	2011-05-27	Teva Pharma	Tannate salt of rasagiline
UA97502C2 (ru) *	2006-12-14	2012-02-27	Тева Фармасьютікл Індастріз, Лтд.	Кристаллическая твердая основа разагилина
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) *	2007-09-05	2010-12-09	テバファーマシューティカルインダストリーズリミティド	ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20090181086A1 (en) *	2008-01-11	2009-07-16	Muhammad Safadi	Rasagiline formulations, their preparation and use
US20110105788A1 (en) *	2008-03-28	2011-05-05	Medichem, S.A.	Polymorphic Form of an Aminoindan Mesylate Derivative
NZ589486A (en)	2008-06-02	2012-08-31	Generics Uk Ltd	A process for the preparation of enantiomerically pure 1-(R)-(2-propynylamino)indan
NZ589470A (en) *	2008-06-02	2012-08-31	Generics Uk Ltd	A process for the preparation of rasagiline and its analogues
ES2389353T3 (es) *	2008-06-10	2012-10-25	Teva Pharmaceutical Industries Ltd.	Cápsulas de gelatina blanda de rasagilina
WO2009151625A1 (en) *	2008-06-13	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline for parkinson's disease modification
US8334409B2 (en) *	2008-06-19	2012-12-18	Teva Pharmaceutical Industries, Ltd.	Process for purifying rasagiline base
CN102065853A (zh) *	2008-06-19	2011-05-18	泰华制药工业有限公司	制备和干燥固体雷沙吉兰碱的方法
WO2011012140A2 (en)	2008-07-11	2011-02-03	Synthon Bv	Polymorphs of rasagiline hydrochloride
CN102149671A (zh) *	2008-07-30	2011-08-10	基因里克斯(英国)有限公司	甲磺酸雷沙吉兰的多晶形式
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
EP2218444A3 (en)	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
JP2012523393A (ja) *	2009-04-09	2012-10-04	エム・エス・ディー・オス・ベー・フェー	インダン誘導体
ES2503015T3 (es)	2009-07-09	2014-10-06	Ratiopharm Gmbh	Sales de rasagilina y sus preparaciones farmacéuticas
CN102048717B (zh) †	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2325159A1 (en)	2009-11-24	2011-05-25	LEK Pharmaceuticals d.d.	Novel salts of rasagiline
US8741962B2 (en) *	2009-11-26	2014-06-03	Usv Limited	Process for preparation of Rasagiline and salts thereof
WO2011087791A1 (en)	2009-12-22	2011-07-21	Teva Pharmaceutical Industries Ltd.	3-keto-n-propargyl-1-aminoindan
CN102791258B (zh)	2010-02-03	2018-05-08	图必制药公司	雷沙吉兰的延长释放制剂及其用途
KR20120137373A (ko)	2010-04-30	2012-12-20	테이코쿠 팔마 유에스에이, 인코포레이티드	프로필아미노인단 경피 조성물
WO2012015946A1 (en)	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Dispersion of rasagiline citrate
CA2806740A1 (en)	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
EP2611440B1 (en)	2010-09-01	2017-02-01	Tonix Pharmaceuticals, Inc.	Treatment for cocaine addiction
BR112013010308A2 (pt)	2010-10-26	2016-07-05	Teva Pharma	rasagilina de deutério enriquecido
WO2012125020A1 (en) *	2011-03-14	2012-09-20	N.V. Nutricia	Method for treating neurotrauma
KR101853082B1 (ko)	2011-03-24	2018-04-27	테이코쿠 팔마 유에스에이, 인코포레이티드	활성제층 및 활성제 변환층을 포함하는 경피 조성물
MX2014004308A (es)	2011-10-10	2014-07-24	Teva Pharma	R(+)-n-formil-propargil-aminoindan.
EP2766004A4 (en) *	2011-10-10	2015-04-22	Teva Pharma	R (+) - N-methyl-propargyl-aminoindan
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
EA201491734A1 (ru)	2012-03-21	2015-01-30	Синтон Бв	Стабилизированные фармацевтические композиции, содержащие соли разагилина
WO2013175493A1 (en)	2012-04-09	2013-11-28	Cadila Healthcare Limited	Stable oral pharmaceutical compositions
US9308182B2 (en)	2012-08-17	2016-04-12	Teva Pharmaceutical Industries, Ltd.	Parenteral formulations of rasagiline
US10918607B2 (en)	2012-11-02	2021-02-16	Teikoku Pharma Usa, Inc.	Propynylaminoindan transdermal compositions
ES2502140T1 (es) *	2013-02-06	2014-10-02	Galenicum Health S.L.	Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2524865T1 (es) *	2013-02-06	2014-12-15	Galenicum Health S.L.	Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
CN105163729A (zh) *	2013-03-13	2015-12-16	N到B有限公司	用于治疗与帕金森氏病相关的运动和抑郁症状的方法、组合物和装置
CN103804200B (zh) *	2014-02-21	2015-04-29	常州市第四制药厂有限公司	雷沙吉兰及其类似物的制备方法
WO2020214886A1 (en) *	2019-04-17	2020-10-22	Vici Health Sciences LLC	Liquid pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US513244A (en) *		1894-01-23		Island
US3201470A (en) *		1965-08-17		Chsx c cech
US3253037A (en) *	1962-06-19	1966-05-24	Ciba Geigy Corp	N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) *	1966-07-16	1970-04-08	Aspro Nicholas Ltd	Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1037014A (en)	1963-08-02	1966-07-20	Aspro Nicholas Ltd	Derivatives of 1-aminoindane
US3513249A (en) *	1968-12-24	1970-05-19	Ideal Ind	Explosion connector with improved insulating means
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
DE3779500T2 (de) *	1986-06-10	1993-01-21	Chiesi Farma Spa	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ES2052593T3 (es)	1986-08-21	1994-07-16	Roussel Uclaf	Procedimiento para preparar derivados del indano.
HU197510B (en)	1986-12-19	1989-04-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4855326A (en)	1987-04-20	1989-08-08	Fuisz Pharmaceutical Ltd.	Rapidly dissoluble medicinal dosage unit and method of manufacture
CA1327795C (en)	1987-08-14	1994-03-15	Jules Freedman	Antidepressants which are aryloxy inadanamines
FR2626877B1 (fr)	1988-02-05	1991-04-05	Delalande Sa	Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique
HU208484B (en)	1988-08-17	1993-11-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
GB8909793D0 (en)	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
US5079018A (en)	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
JPH04504760A (ja)	1989-09-25	1992-08-20	アメリカ合衆国	炎症性反応の検出およびストレスに対する応答の予測をするための評価方法
ES2097155T3 (es)	1989-10-02	1997-04-01	Cima Labs Inc	Forma de dosificacion efervescente y metodo de administracion.
FR2655044B1 (fr)	1989-11-24	1995-03-03	Delalande Sa	Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique.
JPH03176457A (ja)	1989-12-04	1991-07-31	Nippon Paint Co Ltd	新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039742A1 (en)	1990-04-23	1991-10-24	Andrew B. Dennis	Tablet composition and method for problem pharmaceutical materials
US5169868A (en)	1991-03-01	1992-12-08	University Of Saskatchewan	Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) *	1991-04-04	1995-08-22	University Of Toronto, Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5767164A (en) *	1991-04-04	1998-06-16	Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
IL99759A (en)	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
AU666509B2 (en)	1991-12-24	1996-02-15	Yamanouchi Pharmaceutical Co., Ltd.	Intrabuccally disintegrating preparation and production thereof
US5298261A (en)	1992-04-20	1994-03-29	Oregon Freeze Dry, Inc.	Rapidly distintegrating tablet
AU4534593A (en)	1992-06-12	1994-01-04	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
SE501848C2 (sv)	1992-11-18	1995-06-06	Kvaerner Pulping Tech	Metod att koka massa kontinuerligt vid konstant temperatur
IL111240A (en)	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en)	1994-03-01	1999-11-30	Gergely Gerhard	Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
PL183266B1 (pl)	1995-03-02	2002-06-28	Scherer Ltd R P	Doustna kompozycja farmaceutyczna,sposób wytwarzania doustnej kompozycji farmaceutycznej oraz zastosowanie doustnej kompozycji farmaceutycznej
IL115357A (en)	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1052983A2 (en) *	1998-01-27	2000-11-22	Thomas N. Thomas	Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
FI104042B1 (fi) *	1998-09-29	1999-11-15	Aaro Kiuru	Menetelmä keuhkojen perfuusion mittaamiseksi
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7776345B2 (en) *	2001-07-04	2010-08-17	Sun Pharma Advanced Research Company Ltd	Gastric retention controlled drug delivery system
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040166159A1 (en) *	2002-05-29	2004-08-26	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060009483A1 (en) *	2002-05-31	2006-01-12	Bayer Pharmaceuticals Corporation	Compounds and compositions for the treatment of diabetes and diabetes-related disorders
AU2003288902A1 (en) *	2002-09-06	2004-04-08	Genteric, Inc.	Microcapsules and methods of use
EP2526944B1 (en) *	2002-11-15	2016-06-01	Teva Pharmaceutical Industries Limited	Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20050026979A1 (en) *	2003-07-31	2005-02-03	Maha Ghazzi	Methods for treating inflammation and inflammation-associated diseases with a statin and ether
KR20070111534A (ko) *	2005-02-23	2007-11-21	테바 파마슈티컬 인더스트리즈 리미티드	함량 균일성이 개선된 라사길린 제형

1995
- 1995-05-22 US US08/446,439 patent/US5744500A/en not_active Expired - Lifetime
1996
- 1996-05-14 IL IL11824796A patent/IL118247A/en not_active IP Right Cessation
- 1996-05-22 PL PL96323470A patent/PL184124B1/pl not_active IP Right Cessation
- 1996-05-22 KR KR1019970708371A patent/KR100412154B1/ko not_active Expired - Fee Related
- 1996-05-22 HU HU9901629A patent/HUP9901629A3/hu unknown
- 1996-05-22 CZ CZ19973699A patent/CZ288724B6/cs not_active IP Right Cessation
- 1996-05-22 CN CN96195710A patent/CN1096853C/zh not_active Expired - Fee Related
- 1996-05-22 NZ NZ308866A patent/NZ308866A/en not_active IP Right Cessation
- 1996-05-22 BR BR9608733-1A patent/BR9608733A/pt not_active Application Discontinuation
- 1996-05-22 CA CA002221458A patent/CA2221458A1/en not_active Abandoned
- 1996-05-22 EP EP96920401A patent/EP0828485A4/en not_active Ceased
- 1996-05-22 SK SK1574-97A patent/SK283675B6/sk unknown
- 1996-05-22 RU RU97121002/14A patent/RU2203653C2/ru not_active IP Right Cessation
- 1996-05-22 MX MX9708977A patent/MX9708977A/es unknown
- 1996-05-22 US US08/952,705 patent/US6316504B1/en not_active Expired - Lifetime
- 1996-05-22 JP JP53584496A patent/JP3341898B2/ja not_active Expired - Fee Related
- 1996-05-22 AU AU58723/96A patent/AU699090B2/en not_active Expired
- 1996-05-22 WO PCT/US1996/007465 patent/WO1996037199A1/en not_active Ceased
- 1996-05-22 EE EE9700310A patent/EE03741B1/xx not_active IP Right Cessation
1997
- 1997-11-20 NO NO975331A patent/NO975331L/no not_active Application Discontinuation
- 1997-12-22 LT LT97-200A patent/LT4455B/lt not_active IP Right Cessation
1998
- 1998-01-20 LV LVP-97-267A patent/LV12083B/en unknown
2001
- 2001-10-26 US US10/016,268 patent/US6630514B2/en not_active Expired - Fee Related
2002
- 2002-11-27 US US10/305,478 patent/US6956060B2/en not_active Expired - Fee Related
2005
- 2005-06-17 US US11/155,864 patent/US20060094783A1/en not_active Abandoned
2006
- 2006-11-10 US US11/595,726 patent/US20070100001A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2221458A1 (en)	1996-11-28
MX9708977A (es)	1998-03-31
CZ369997A3 (cs)	1999-06-16
IL118247A (en)	2002-07-25
LV12083A (lv)	1998-07-20
US20070100001A1 (en)	2007-05-03
KR19990021896A (ko)	1999-03-25
AU699090B2 (en)	1998-11-19
HK1015269A1 (en)	1999-10-15
EP0828485A1 (en)	1998-03-18
PL184124B1 (pl)	2002-09-30
JP2000508292A (ja)	2000-07-04
NO975331D0 (no)	1997-11-20
WO1996037199A1 (en)	1996-11-28
SK283675B6 (sk)	2003-11-04
NO975331L (no)	1998-01-20
RU2203653C2 (ru)	2003-05-10
US5744500A (en)	1998-04-28
WO1996037199A8 (en)	1999-08-12
HUP9901629A2 (hu)	2000-02-28
US20060094783A1 (en)	2006-05-04
US6316504B1 (en)	2001-11-13
LT97200A (en)	1998-09-25
PL323470A1 (en)	1998-03-30
US20030065038A1 (en)	2003-04-03
HUP9901629A3 (en)	2000-03-28
JP3341898B2 (ja)	2002-11-05
IL118247A0 (en)	1996-09-12
US20030212145A1 (en)	2003-11-13
NZ308866A (en)	1999-09-29
KR100412154B1 (ko)	2004-07-05
BR9608733A (pt)	1999-12-07
EE9700310A (et)	1998-06-15
CN1191481A (zh)	1998-08-26
LV12083B (en)	1998-09-20
SK157497A3 (en)	1998-05-06
CN1096853C (zh)	2002-12-25
LT4455B (lt)	1999-01-25
US6956060B2 (en)	2005-10-18
US6630514B2 (en)	2003-10-07
CZ288724B6 (cs)	2001-08-15
EP0828485A4 (en)	1998-12-02
AU5872396A (en)	1996-12-11

Publication	Publication Date	Title
EE03741B1 (et)	2002-06-17	N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
FI955235A7 (fi)	1996-05-03	Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
FI941378L (fi)	1994-09-25	Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus
FI940904A7 (fi)	1994-11-29	Oksatsolidiinidionijohdannaiset, niiden valmistus ja käyttö
EE200000468A (et)	2002-04-15	Ühendid, nende kasutamine ja farmatseutiline kompositsioon
FI945281A7 (fi)	1995-05-11	Heterosykliset yhdisteet, niiden valmistus ja käyttö
EE9900018A (et)	1999-08-16	Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
FI972313L (fi)	1997-07-30	Uusia 2,3-diketopiperatsiinijohdannaisia ja niiden suoloja
EE03486B1 (et)	2001-08-15	Pürasool-4-üülbensoüüli derivaadid ja nende kasutamine herbitsiididena
FI962589L (fi)	1996-08-20	2,4-disulfofenyylibutyylinitroni, sen suolat ja niiden käyttö farmaseuttisina aineina
FI912327A7 (fi)	1991-11-16	Kloorideoksisokerimakeutusainekoostumus, ja sen käyttö
FI972629A7 (fi)	1997-06-18	Aryyli- ja heteroaryylisulfonamidijohdoksia, niiden valmistus ja niiden käyttö endoteliinin antagonisteina
FI964031L (fi)	1996-10-08	Bentsamidijohdannainen, mainittua johdannaista sisältävät koostumukset ja sen käyttö
FI970997A7 (fi)	1997-03-10	Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö
FI972306A0 (fi)	1997-05-30	Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FI972988A0 (fi)	1997-07-14	Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
FI954229L (fi)	1995-09-08	Heterosykliset yhdisteet, niiden käyttö ja valmistus
FI930716A7 (fi)	1993-08-21	Uusia aryylikarbonyyliaminoalkyylidihydro-oksopyridiinejä, niiden valmistus ja käyttö
FI944040A7 (fi)	1995-03-04	Laktolijohdannaiset, niiden valmistus ja käyttö
EE9800054A (et)	1998-08-17	Pürasool-4-üül-bensoüüli derivaadid ja nende kasutamine herbitsiididena
FI971317A7 (fi)	1997-03-27	Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
FI941214A7 (fi)	1994-09-16	Bentsimidatsolin johdannaisia, niiden valmistus ja käyttö
FI965172A7 (fi)	1997-02-21	Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
EE9800085A (et)	1998-12-15	3,5-difluoropüridiinid, nende valmistamismeetod, herbitsiidne kompositsioon ja nende kasutamine
FI952855L (fi)	1995-06-09	Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-10-17	AA1Y	Spc filed	Free format text: PRODUCT NAME: AZILECT; REG NO/DATE: (EMEA/H/C/574) 21.02.2005 Spc suppl protection certif: C20050006 Filing date: 20050822
2005-10-17	FG1Y	Spc granted	Free format text: PRODUCT NAME: AZILECT; REG NO/DATE: (EMEA/H/C/574) 21.02.2005 Spc suppl protection certif: C20050006 00009 Filing date: 20050822 Extension date: 20190221
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	MC1Y	Annulment of an spc	Spc suppl protection certif: 00009
2008-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20070522